A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Efficcacy, Safety, and Pharmacokinetics of Harmacokinetics of PF-06480605 in Adult Participants with Moderate to Severe Ulcerative Colitis

Grants and Contracts Details

StatusFinished
Effective start/end date8/4/20 → 6/20/22

Funding

  • Pfizer Inc.: $18,044.00